Answers are grounded in this paper and cite their sources.
Background: D-isoascorbic acid (D-VC), also known as erythorbic acid, and arsenic trioxide (ATO) have shown antitumour effects in preclinical models of KRAS-mutant colorectal cancer (CRC); however, clinical evidence in refractory disease is limited. Case Presentation: A 43-year-old man with heavily pretreated, microsatellite-stable (MSS) metastatic CRC underwent treatment with ATO and D-VC. Serial CT examinations showed little interval change in the dimensions of two selected pulmonary metastatic lesions between December 2023 and February 2024. However, following the initial courses of D-VC in combination with ATO in 2023, radiological progression was documented on 2 July 2024, before D-VC monotherapy was reintroduced and the dose was subsequently escalated. Next-generation sequencing of the primary tumour, followed by expert variant annotation, identified a complex genomic profile, including concurrent somatic KRAS p.Gly12Cys and PIK3CA p.Glu542Lys alterations. A PRKN p.Arg275Trp variant was also annotated as potentially germline in origin; however, its constitutional status could not be independently confirmed because matched non-tumour DNA was unavailable. The potential implications of this variant for mitophagy and mitochondrial quality control remain hypothetical. Conclusions: This single-patient observation does not establish clinical efficacy or predictive biomarkers for ATO/D-VC therapy. It illustrates the complementary information of tumour molecular profiling and clinical observations in characterising refractory CRC and underscores the importance of appropriate germline assessment when potentially germline variants are identified. Prospective clinical studies and functional investigations are required to clarify the molecular determinants of response and resistance to the ATO/D-VC combination.
No takes yet. Share an insight, caveat, or question.
Aitkulova et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: